Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 12/20 | 0.54 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743938 | 0.81 | FAAH (0.57) | CCR3 | |
| SCHEMBL5743942 | 0.81 | FAAH (0.57) | CCR3 | |
| SCHEMBL3354932 | 0.79 | CCR3 (0.59) | CCR3FPR2PROKR1 | |
| SCHEMBL4960083 | 0.79 | CCR3 (0.53) | CCR3FPR2PROKR1 | |
| SCHEMBL5743381 | 0.79 | CCR3 (0.53) | CCR3FPR2PROKR1 | |
| SCHEMBL4958711 | 0.77 | KMT2A (0.56) | CCR3 | |
| SCHEMBL4958716 | 0.77 | KMT2A (0.56) | CCR3 | |
| SCHEMBL5740997 | 0.77 | KMT2A (0.56) | CCR3 | |
| SCHEMBL4959461 | 0.77 | CCR3 (0.57) | CCR3FPR2PROKR1 | |
| SCHEMBL5744458 | 0.77 | CCR3 (0.57) | CCR3FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680408-A2 | CCR3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005040129-A2 | CCR3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20050090504-A1 | Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists | ROCHE PALO ALTO LLC | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090504-A1 | Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists | CCR9, CCR3, CCR1 | CCR3 2/4885FPR2 81/4885PROKR1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.